REEUF

11.6900.00%
DK

Daniel Karp

Independent Director

Mr. Daniel Karp serves as Chief Strategy Officer at Organon & Co. since February 2026 and is Head of Corporate Development and was Executive Vice President of Corporate Development and served as its Head of Corporate Development since 2025 & Chief Strategy Officer since 2025 until 2025 and served as its Executive Vice President of Corporate Development since October 2024 until 2025 and served as its Chief Business Development Officer until October 2024. He is Independent Director at Cartesian Growth Corporation since February 26, 2021. Mr. Karp was Senior Vice President, Head of Business Development for Organon & Co. since January 2021, a wholly owned subsidiary of Merck & Co. scheduled to spin off as a separate company in 2021. He serves as Independent Director of Cartesian Growth Corporation II since May 5, 2022. He served as Executive Vice President of Corporate Development at Biogen Inc. from June 11, 2018 until March 2020. Mr. Karp led the newly created Corporate Development function, which includes corporate and business development and corporate strategy. He joined Biogen from Pfizer Inc. where he most recently was Vice President, Worldwide Business Development from December 2010 to December 2013, as Director, Worldwide Business Development from January 2008 to December 2010, as Senior Manager, Worldwide Business Development from May 2007 to December 2007 and as Manager, U.S. Business Development from July 2006 to April 2007 and head of business development for Worldwide Research and Development from May 2016 to June 2018. In that role, he led a global team responsible for early science transactions, partnerships and acquisitions across Pfizer’s research portfolio. In over a decade at Pfizer, he held corporate and business development roles spanning rare diseases, gene therapy, vaccines, oncology and specialty care, with experience including mergers and acquisitions, licensing and scientific collaborations. In recent years, he has been involved in several high-profile acquisitions and led business development organizations that executed hundreds of agreements, licenses and collaborations. His experience also includes healthcare and life sciences strategy consulting. He holds a BS in Biology from Duke University and an MBA from the Wharton School of Business at the University of Pennsylvania.

Positions